Third, in the rodent olfactory bulbectomy depression model, EPA treatment normalized depressive behaviors by attenuating prostaglandin E2-mediated activation of IL-6, decreasing mRNA expression for corticotrophin-releasing hormone (CRH) and inhibiting hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis52. The gene discussed is CRH; the disease is depressive disorder.